Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Nerandomilast · לא צוין

מזהה רישום
NCT07919015
שלב
לא צוין
סטטוס
מגייס
תרופה / התערבות
Nerandomilast
ממן
Avraham Unterman
מספר משתתפים
70
מיקומים
4

על הניסוי

Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them. The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy. The main goal is to find out whether lung fu

צפו ב-NCT07919015 ב-ClinicalTrials.gov ←

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT07919015 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.